Vancomycin plus Rifampin — Competitive Intelligence Brief

Vancomycin plus Rifampin (Vancomycin plus Rifampin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

marketed Antibiotic combination Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin) Infectious Disease Small molecule

Target snapshot

Vancomycin plus Rifampin (Vancomycin plus Rifampin) — Michael E. DeBakey VA Medical Center. Vancomycin and rifampin work synergistically to inhibit bacterial cell wall and protein synthesis, providing broad-spectrum bactericidal activity against resistant gram-positive organisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin plus Rifampin TARGET	Vancomycin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin) and bacterial RNA polymerase (rifampin)
Different Antibiotic Combinations	Different Antibiotic Combinations	Inonu University	marketed	Antibiotic combinations	Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
Acnatac® Gel left face	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Vonoprazan + amoxicillin + clarithromycin	Vonoprazan + amoxicillin + clarithromycin	The Third Xiangya Hospital of Central South University	marketed	Proton pump inhibitor + antibiotic combination	H+ K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class